These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31287406)

  • 1. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.
    Macaluso F; Guggino G; Mauro D; Rizzo C; Bignone R; Ciccia F
    Clin Exp Rheumatol; 2019; 37(6):1096. PubMed ID: 31287406
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
    Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Macaluso F; Guggino G; Ciccia F
    Clin Exp Rheumatol; 2021; 39(1):224. PubMed ID: 32452343
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
    Nisar MK
    Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
    RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
    Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
    Cortese A; Lucchetti R; Altobelli A; Conte A; Primavera M; Valesini G; Millefiorini E; Scrivo R
    Mult Scler Relat Disord; 2019 Oct; 35():193-195. PubMed ID: 31398658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of secukinumab for the treatment of active ankylosing spondylitis.
    Loricera J; Galíndez-Aguirregoikoa E; Blanco R
    Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
    [No Abstract]   [Full Text] [Related]  

  • 9. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
    Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
    Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
    [No Abstract]   [Full Text] [Related]  

  • 10. Ixekizumab for the treatment of ankylosing spondylitis.
    Huang JX; Lee YH; Wei JC
    Expert Rev Clin Immunol; 2020 Aug; 16(8):745-750. PubMed ID: 32729361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
    Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
    Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 13. Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience.
    Bulut Gökten D; Mercan R
    Clin Exp Rheumatol; 2024 Mar; 42(3):767. PubMed ID: 37877409
    [No Abstract]   [Full Text] [Related]  

  • 14. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report.
    Currado D; Margiotta D; Conforti C; Coppola R; Panasiti V; Afeltra A; Navarini L
    Scand J Rheumatol; 2020 Jan; 49(1):75-76. PubMed ID: 31262212
    [No Abstract]   [Full Text] [Related]  

  • 16. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
    Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
    Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R
    Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M; Taniguchi A; Fujishige A; Kaneko S; Haemmerle S; Porter BO; Kobayashi S
    Mod Rheumatol; 2020 Jan; 30(1):132-140. PubMed ID: 30334633
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis.
    Sakellariou GT; Konsta M; Katsigianni I; Deligeorgakis D; Zisopoulos D; Vounotrypidis P
    Int J Rheum Dis; 2023 Dec; 26(12):2603-2606. PubMed ID: 37432022
    [No Abstract]   [Full Text] [Related]  

  • 20. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
    Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
    Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.